Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

US12303516B2 · kind B2 · utility

Assignee

• Egetis Therapeutics AB · SE

Inventors

• Jacques Näsström · Bromma, SE
• Sven Jacobsson · Stockholm, SE
• Dennis Henriksen · Lincoln, US
• James Van Alstine · Stockholm, SE

Key dates

• Filing date: Jan 14, 2022
• Grant date: May 20, 2025
• Expiry date: Jan 15, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P13/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent comprising N-acetylcysteine and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.